GSK Hails Success For Novel Antibiotic – But Reaching $1bn Sales Will Be A Challenge
Company Expects To File In H1 2023
GSK is returning to its long heritage in antibiotics with a potential first-in-class drug that has just shown promise in urinary tract infection; hopes are that it can reach annual sales of $1bn.
You may also be interested in...
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.
GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.
GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.